Want to see NGEN full AI Analyst Report?
Top Page
NervGen Pharma
(NASDAQ:NGEN)
Select Model
Select Model
Rating:41Neutral
Price Target:
$1.50
▼(-32.13% Downside)
Action:Reiterated
Date:10/15/26
The score is primarily weighed down by weak financial performance (no revenue, widening losses, and increasing cash burn that implies ongoing financing needs) and bearish technicals (trading below all major moving averages with negative MACD and oversold momentum). Valuation provides limited support because the negative P/E reflects losses and there is no dividend yield data.
Positive Factors
Focused clinical pipeline
A focused lead program gives NervGen a clear development strategy centered on nervous-system repair, while potential use across multiple neurological indications could broaden the commercial opportunity if clinical evidence supports expansion beyond spinal cord injury.
Negative Factors
Pre-revenue business model
NervGen currently lacks recurring product revenue, so its operations depend on advancing clinical assets rather than funding development through customer sales. This leaves future value highly dependent on clinical and regulatory progress and the eventual success of commercialization.
Read all positive and negative factors
Positive Factors
Negative Factors
Focused clinical pipeline
A focused lead program gives NervGen a clear development strategy centered on nervous-system repair, while potential use across multiple neurological indications could broaden the commercial opportunity if clinical evidence supports expansion beyond spinal cord injury.
Read all positive factors
NervGen Pharma (NGEN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$165.73M
Dividend YieldN/A
Average Volume (3M)470.04K
Price to Earnings (P/E)―
Beta (1Y)0.56
Revenue GrowthN/A
EPS Growth18.13%
CountryUS
Employees11
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.85
Shares Outstanding107,616,410
10 Day Avg. Volume435,497
30 Day Avg. Volume470,042
Financial Highlights & Ratios
PEG Ratio-0.18
Price to Book (P/B)159.85
Price to Sales (P/S)0.00
P/FCF Ratio-28.50
Enterprise Value/Market Cap0.94
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-12.41K
Enterprise Value/Ebitda-13.38
Forecast
1Y Price Target
$10.00Price Target Upside352.49% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.43
Revenue Forecast (FY)N/A
NervGen Pharma Business Overview & Revenue Model
Company Description
NervGen Pharma Corp., along with its affiliated entities, is a pharmaceutical company dedicated to discovering, advancing, and commercializing innovative drug therapies for neurological conditions involving nerve damage. Its flagship investigation...
How the Company Makes Money
NervGen Pharma does not have a mature commercial product portfolio; as a clinical-stage biotech, it is primarily focused on advancing its drug candidates through clinical development rather than generating recurring product sales. Information indi...
NervGen Pharma Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
46
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -12.52K | 0.00 | -83.74K | -145.01K | -114.10K | -42.95K |
| EBITDA | -11.61M | -5.65M | -23.91M | -22.24M | -19.92M | -12.78M |
| Net Income | -67.56M | -44.12M | -23.99M | -22.38M | -20.54M | -12.82M |
Balance Sheet | ||||||
| Total Assets | 90.34M | 23.21M | 19.47M | 13.24M | 23.67M | 18.03M |
| Cash, Cash Equivalents and Short-Term Investments | 86.93M | 22.07M | 17.35M | 11.66M | 22.25M | 17.06M |
| Total Debt | 0.00 | 8.37K | 105.53K | 197.21K | 280.96K | 0.00 |
| Total Liabilities | 73.03M | 19.73M | 16.90M | 15.25M | 10.32M | 1.09M |
| Stockholders Equity | 17.31M | 3.48M | 2.57M | -2.01M | 13.34M | 16.95M |
Cash Flow | ||||||
| Free Cash Flow | -29.60M | -19.50M | -16.83M | -11.30M | -17.65M | -8.33M |
| Operating Cash Flow | -29.60M | -19.50M | -16.83M | -11.30M | -17.63M | -8.33M |
| Investing Cash Flow | 80.48K | 100.93K | 58.83K | -138.87K | -20.92K | -45.43K |
| Financing Cash Flow | 102.69M | 23.76M | 22.68M | 766.35K | 22.44M | 19.76M |
NervGen Pharma Technical Analysis
Negative
2.21
Price Trends
1.93
Negative
1.88
Negative
2.97
Negative
Market Momentum
-0.13
Positive
25.48
Positive
2.75
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NGEN, the sentiment is Negative. The current price of 2.21 is above the 20-day moving average (MA) of 1.70, above the 50-day MA of 1.93, and below the 200-day MA of 2.97, indicating a bearish trend. The MACD of -0.13 indicates Positive momentum. The RSI at 25.48 is Positive, neither overbought nor oversold. The STOCH value of 2.75 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NGEN.
NervGen Pharma Peers Comparison
UnderperformOutperform
Sector (51)
NGEN
NervGen Pharma
1.42
-1.33
-48.40%
TSE:DRUG
Bright Minds Biosciences
73.18
-12.57
-14.66%
TSE:MYND
MYND Life Sciences
0.07
0.00
0.00%
TSE:MBIO
Mindbio Therapeutics Corp.
0.13
-3.88
-96.88%
TSE:NURL
Neural Therapeutics Inc.
0.02
<0.01
50.00%
NervGen Pharma Corporate Events
NervGen Pharma Flags Non-Cash Accounting Errors, Orders Restatement of 2024–2026 Results
Sep 25, 2026
On September 25, 2026, NervGen Pharma’s audit committee, following consultation with management and its auditors KPMG Canada and KPMG US, determined that investors should no longer rely on its audited financial statements for fiscal years 20...
NervGen Pharma Appoints KPMG US as New Auditor After Canadian Resignation
Sep 24, 2026
On September 15, 2026, NervGen Pharma Corp. requested the resignation of KPMG LLP (Canada) as its auditor and, effective the same date, appointed KPMG LLP (US) to fill the vacancy, a move that was reviewed and approved by the company’s audit...
NervGen Pharma Posts Larger Q2 2026 Loss but Strengthens Cash Position
Aug 13, 2026
NervGen Pharma Corp., a Vancouver-based biotechnology company specializing in nervous system repair therapeutics, reported its unaudited condensed consolidated interim financial results for the three- and six-month periods ended June 30, 2026, alo...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.